[Can Echocardiography Adjust Corrected Contrast Injection Condition in Coronary CT Angiography?]

PURPOSE: The purposes were to search which factor of cardiac function in echocardiography correlates with the CT value, to correct contrast injection conditions with cardiac function in addition to suppress error in the contrast effect between patients, and to achieve the target CT value (350 HU) in coronary computed tomography angiography (CCTA). METHODS: In 112 patients (conventional group), the contrast material was administered at a fractional dose (FD) of 21 mgI/kg/s. We measured the aortic CT value in the coronary origin part. In 112 patients (correction group), the contrast material was administered at corrected injection conditions with the most correlated functional factor and CT value. RESULTS: The CT value of the conventional group was an average of 400.8±51.5 HU. The most correlated factor with the CT value was stroke volume [SV (r=-0.555)]. The CT value of the conventional group was an average of 360±46 HU. The case of the aim CT level was improved from 46% to 74%. In the correction group, the average value of FD was 18.5 mgI/kg/s. This enabled the reduction of the contrast material in 95% of patients. CONCLUSION: The best correlation was obtained between the CT value of coronary arteries and SV. The contrast medium injection conditions were corrected for cardiac function in addition to body weight. As a result, we were able to control the CCTA target CT value of 300 to 400 HU at our hospital.

Connexin 43 expression is associated with poor survival in patients with esophageal squamous cell carcinoma.

Connexin 43 (Cx43) is an important gap junction protein in vertebrates, which has been reported to function as a tumor suppressor in a number of organs. However, the mechanism underlying the effect of Cx43 on tumor progression remains unknown, with only a limited number of studies reporting on the role of Cx43 in esophageal cancer. In the present study, Cx43 expression was analyzed by immunohistochemical staining and the associations between Cx43 expression and clinicopathological characteristics or prognosis were evaluated. Cx43 was expressed at a high frequency in patients with esophageal squamous cell carcinoma (ESCC). Of the 98 ESCC cases investigated, positivity for Cx43 was observed in 62 cases (63.26%). In patients with high Cx43 expression, the survival rates were significantly reduced compared with those in patients with low Cx43 expression. Moreover, the overexpression of Cx43, as measured by immunohistochemistry, was an independent prognostic indicator of ESCC. Thus, our data indicated that Cx43 may be a candidate molecular prognostic marker and molecular target for the development of an effective therapeutic intervention for patients with esophageal cancer.